BENZENO SHARON 4
4 · Adaptive Biotechnologies Corp · Filed Mar 13, 2026
Research Summary
AI-generated summary of this filing
Adaptive Biotechnologies (ADPT) Sharon Benzeno Sells Shares
What Happened
- Sharon Benzeno, Chief Commercial Officer (Immune Medicine) at Adaptive Biotechnologies, reported a sale of 63,103 shares on 2026-03-11 at $13.17 per share, totaling about $831,067. The Form 4 was filed on 2026-03-13.
- The filing indicates this was a sell-to-cover transaction to satisfy tax withholding on vested RSUs, not a discretionary open-market trade.
Key Details
- Transaction date: 2026-03-11; reported on Form 4 filed 2026-03-13 (timely).
- Type: Sale (reported as open-market or private sale); 63,103 shares at $13.17 each; proceeds ≈ $831,067.
- Footnote: Sale required to cover tax withholding for RSU vesting (issuer-mandated "sell to cover"); not a discretionary trade by the reporting person (Footnote F1).
- Shares owned after transaction: not specified in the provided filing.
- Accession (for reference): 0001780854-26-000004.
Context
- Sell-to-cover transactions occur when an insider’s restricted stock units vest and the company requires withholding taxes to be satisfied by selling a portion of the shares. These are routine and generally do not signal a change in the insider’s view of the company.
- For retail investors, purchases typically carry more informational weight than mandated sell-to-cover sales; treat this filing as a tax-related liquidity event rather than an investment decision.
Insider Transaction Report
Form 4
BENZENO SHARON
Chief Commercial Ofc Imm Med
Transactions
- Sale
Common Stock
[F1]2026-03-11$13.17/sh−63,103$831,067→ 272,751 total
Footnotes (1)
- [F1]This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Signature
/s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact|2026-03-13